Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $66.00.

Several research firms recently commented on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, May 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $71.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Thursday, June 27th. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 target price for the company. Finally, StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, May 13th.

Insider Transactions at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 3,596 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total value of $147,184.28. Following the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO William J. Peters sold 3,596 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $40.93, for a total value of $147,184.28. Following the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $3,851,635.79. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the transaction, the director now directly owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Insiders sold a total of 7,596 shares of company stock valued at $313,544 in the last three months. 27.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 7.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 379,480 shares of the company’s stock worth $23,471,000 after buying an additional 27,102 shares in the last quarter. Epoch Investment Partners Inc. raised its holdings in Amphastar Pharmaceuticals by 348.7% in the 4th quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock valued at $36,648,000 after acquiring an additional 460,473 shares during the last quarter. TD Asset Management Inc lifted its stake in Amphastar Pharmaceuticals by 449.0% in the 4th quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after purchasing an additional 649,001 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 870.9% during the 4th quarter. Victory Capital Management Inc. now owns 237,474 shares of the company’s stock worth $14,688,000 after purchasing an additional 213,014 shares during the last quarter. Finally, Shaker Investments LLC OH grew its position in shares of Amphastar Pharmaceuticals by 136.0% in the fourth quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock valued at $3,035,000 after purchasing an additional 28,283 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 3.7 %

NASDAQ:AMPH opened at $38.51 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. The company’s fifty day moving average price is $41.58 and its 200-day moving average price is $47.62. Amphastar Pharmaceuticals has a 1-year low of $37.46 and a 1-year high of $67.66. The firm has a market capitalization of $1.88 billion, a P/E ratio of 13.33, a PEG ratio of 0.82 and a beta of 0.80.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.73 by $0.20. The company had revenue of $171.84 million for the quarter, compared to analyst estimates of $171.13 million. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. As a group, equities research analysts anticipate that Amphastar Pharmaceuticals will post 3.6 EPS for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.